Antibody therapeutics for epithelial ovarian cancer.

ABSTRACT:

Introduction

High-grade serous ovarian carcinoma (HGSC) is an aggressive subtype of epithelial ovarian carcinoma (EOC) and remains the most lethal gynecologic cancer. A lack of effective and tolerable therapeutic options and nonspecific symptoms at presentation with advanced stage of disease are among the challenges in the management of the disease.

Areas covered

An overview of ovarian cancer, followed by a discussion of the current therapeutic regimes and challenges that arise during and after the treatment of EOC. We discuss different formats of antibody therapeutics and their usage in targeting validated targets implicated in ovarian cancer, as well as three emerging novel proteins as examples recently implicated in their contribution to adaptive resistance in ovarian can

SUBMITTER: Ruiz M 

PROVIDER: S-EPMC10375545 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature